These findings suggest that MIF contributes to psoriasiform dermatitis pathogenesis through multiple mechanisms, particularly in IL-23-driven pathways, positioning it as a possible therapeutic target [15]. The gene discussed is IL23A; the disease is Psoriasiform dermatitis.